Japan’s Shionogi & Co. Ltd. said on Wednesday its oral treatment for COVID-19 demonstrated a significant reduction in symptoms compared with a placebo in a Phase III trial in Asia. The drug, a ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that ...

Japan’s Shionogi & Co. Ltd. said on Wednesday it had started a Phase II/III clinical trial for its COVID-19 vaccine candidate ...

While Zatolmilast demonstrated an efficacy signal in one study in adults, the drug missed its primary endpoints across the FXS programme.

Integration Fully Operational on Day One to Ensure Continuity of Care for the ALS Community With More than 100 Team Members Joining Shionogi from Tanabe Pharma America Acquisition Establishes a Strong ...

Shionogi & Co., Ltd. reported earnings for the nine months ended December 31, 2025, with sales rising to ¥360,684 million and net income reaching ¥158,225 million, both higher than the same period a ...

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., a United States subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao ...

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved ...

Shionogi has struck a deal to take full control of its sleep disorder joint venture, agreeing to pay Apnimed $100 million upfront for its partner’s half of the business. Shionogi called the joint ...

Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. The company is paying 5 million Swiss francs ($6.3 million) upfront for a preclinical antibiotic ...